Peter Johnson1, Massimo Federico1, Amy Kirkwood1, Alexander Fosså1, Leanne Berkahn1, Angelo Carella1, Francesco d'Amore1, Gunilla Enblad1, Antonella Franceschetto1, Michael Fulham1, Stefano Luminari1, Michael O'Doherty1, Pip Patrick1, Thomas Roberts1, Gamal Sidra1, Lindsey Stevens1, Paul Smith1, Judith Trotman1, Zaid Viney1, John Radford1, Sally Barrington1. 1. From the Cancer Research UK Centre, University of Southampton, Southampton (P.J.), Cancer Research UK and University College London Cancer Trials Centre (A.K., P.P., T.R., L.S., P.S.) and the PET Imaging Centre, King's College London, King's Health Partners, St. Thomas' Hospital (M.O., Z.V., S.B.), London, the Department of Haematology, Lincoln County Hospital, Lincoln (G.S.), and the Department of Medical Oncology, Christie Hospital, Manchester (J.R.) - all in the United Kingdom; the Department of Diagnostic, Clinical, and Public Health Medicine, University of Modena and Reggio Emilia, Modena (M. Federico, A. Franceschetto, S.L.), the Department of Hematology, San Martino University Hospital, Genoa (A.C.), and Arcispedale Santa Maria Nuova-Istituti di Ricovero e Cura a Carattere Scientifico, Reggio Emilia (S.L.) - all in Italy; the Department of Medical Oncology, Oslo University Hospital, Oslo (A. Fosså); the Department of Haematology, Auckland City Hospital, Auckland, New Zealand (L.B.); the Department of Hematology, Aarhus University Hospital, Aarhus, Denmark (F.A.); the Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden (G.E.); and the Department of Molecular Imaging, Royal Prince Alfred Hospital (M. Fulham), and Concord Repatriation General Hospital, University of Sydney (J.T.), Sydney.
Abstract
BACKGROUND: We tested interim positron-emission tomography-computed tomography (PET-CT) as a measure of early response to chemotherapy in order to guide treatment for patients with advanced Hodgkin's lymphoma. METHODS: Patients with newly diagnosed advanced classic Hodgkin's lymphoma underwent a baseline PET-CT scan, received two cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy, and then underwent an interim PET-CT scan. Images were centrally reviewed with the use of a 5-point scale for PET findings. Patients with negative PET findings after two cycles were randomly assigned to continue ABVD (ABVD group) or omit bleomycin (AVD group) in cycles 3 through 6. Those with positive PET findings after two cycles received BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone). Radiotherapy was not recommended for patients with negative findings on interim scans. The primary outcome was the difference in the 3-year progression-free survival rate between randomized groups, a noninferiority comparison to exclude a difference of 5 or more percentage points. RESULTS: A total of 1214 patients were registered; 937 of the 1119 patients (83.7%) who underwent an interim PET-CT scan according to protocol had negative findings. With a median follow-up of 41 months, the 3-year progression-free survival rate and overall survival rate in the ABVD group were 85.7% (95% confidence interval [CI], 82.1 to 88.6) and 97.2% (95% CI, 95.1 to 98.4), respectively; the corresponding rates in the AVD group were 84.4% (95% CI, 80.7 to 87.5) and 97.6% (95% CI, 95.6 to 98.7). The absolute difference in the 3-year progression-free survival rate (ABVD minus AVD) was 1.6 percentage points (95% CI, -3.2 to 5.3). Respiratory adverse events were more severe in the ABVD group than in the AVD group. BEACOPP was given to the 172 patients with positive findings on the interim scan, and 74.4% had negative findings on a third PET-CT scan; the 3-year progression-free survival rate was 67.5% and the overall survival rate 87.8%. A total of 62 patients died during the trial (24 from Hodgkin's lymphoma), for a 3-year progression-free survival rate of 82.6% and an overall survival rate of 95.8%. CONCLUSIONS: Although the results fall just short of the specified noninferiority margin, the omission of bleomycin from the ABVD regimen after negative findings on interim PET resulted in a lower incidence of pulmonary toxic effects than with continued ABVD but not significantly lower efficacy. (Funded by Cancer Research UK and Others; ClinicalTrials.gov number, NCT00678327.).
BACKGROUND: We tested interim positron-emission tomography-computed tomography (PET-CT) as a measure of early response to chemotherapy in order to guide treatment for patients with advanced Hodgkin's lymphoma. METHODS: Patients with newly diagnosed advanced classic Hodgkin's lymphoma underwent a baseline PET-CT scan, received two cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy, and then underwent an interim PET-CT scan. Images were centrally reviewed with the use of a 5-point scale for PET findings. Patients with negative PET findings after two cycles were randomly assigned to continue ABVD (ABVD group) or omit bleomycin (AVD group) in cycles 3 through 6. Those with positive PET findings after two cycles received BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone). Radiotherapy was not recommended for patients with negative findings on interim scans. The primary outcome was the difference in the 3-year progression-free survival rate between randomized groups, a noninferiority comparison to exclude a difference of 5 or more percentage points. RESULTS: A total of 1214 patients were registered; 937 of the 1119 patients (83.7%) who underwent an interim PET-CT scan according to protocol had negative findings. With a median follow-up of 41 months, the 3-year progression-free survival rate and overall survival rate in the ABVD group were 85.7% (95% confidence interval [CI], 82.1 to 88.6) and 97.2% (95% CI, 95.1 to 98.4), respectively; the corresponding rates in the AVD group were 84.4% (95% CI, 80.7 to 87.5) and 97.6% (95% CI, 95.6 to 98.7). The absolute difference in the 3-year progression-free survival rate (ABVD minus AVD) was 1.6 percentage points (95% CI, -3.2 to 5.3). Respiratory adverse events were more severe in the ABVD group than in the AVD group. BEACOPP was given to the 172 patients with positive findings on the interim scan, and 74.4% had negative findings on a third PET-CT scan; the 3-year progression-free survival rate was 67.5% and the overall survival rate 87.8%. A total of 62 patients died during the trial (24 from Hodgkin's lymphoma), for a 3-year progression-free survival rate of 82.6% and an overall survival rate of 95.8%. CONCLUSIONS: Although the results fall just short of the specified noninferiority margin, the omission of bleomycin from the ABVD regimen after negative findings on interim PET resulted in a lower incidence of pulmonary toxic effects than with continued ABVD but not significantly lower efficacy. (Funded by Cancer Research UK and Others; ClinicalTrials.gov number, NCT00678327.).
Authors: Sally F Barrington; Wendi Qian; Edward J Somer; Antonella Franceschetto; Bruno Bagni; Eva Brun; Helén Almquist; Annika Loft; Liselotte Højgaard; Massimo Federico; Andrea Gallamini; Paul Smith; Peter Johnson; John Radford; Michael J O'Doherty Journal: Eur J Nucl Med Mol Imaging Date: 2010-05-27 Impact factor: 9.236
Authors: S Viviani; G Bonadonna; A Santoro; V Bonfante; M Zanini; L Devizzi; F Soncini; P Valagussa Journal: J Clin Oncol Date: 1996-05 Impact factor: 44.544
Authors: S F Barrington; J E MacKewn; P Schleyer; P K Marsden; N G Mikhaeel; W Qian; P Mouncey; P Patrick; B Popova; P Johnson; J Radford; M J O'Doherty Journal: Ann Oncol Date: 2010-09-02 Impact factor: 32.976
Authors: Karolin Behringer; Helen Goergen; Felicitas Hitz; Josée M Zijlstra; Richard Greil; Jana Markova; Stephanie Sasse; Michael Fuchs; Max S Topp; Martin Soekler; Stephan Mathas; Julia Meissner; Martin Wilhelm; Peter Koch; Hans-Walter Lindemann; Enrico Schalk; Robert Semrau; Jan Kriz; Tom Vieler; Martin Bentz; Elisabeth Lange; Rolf Mahlberg; Andre Hassler; Martin Vogelhuber; Dennis Hahn; Jörg Mezger; Stefan W Krause; Nicole Skoetz; Boris Böll; Bastian von Tresckow; Volker Diehl; Michael Hallek; Peter Borchmann; Harald Stein; Hans Eich; Andreas Engert Journal: Lancet Date: 2014-12-22 Impact factor: 79.321
Authors: Oliver W Press; Hongli Li; Heiko Schöder; David J Straus; Craig H Moskowitz; Michael LeBlanc; Lisa M Rimsza; Nancy L Bartlett; Andrew M Evens; Erik S Mittra; Ann S LaCasce; John W Sweetenham; Paul M Barr; Michelle A Fanale; Michael V Knopp; Ariela Noy; Eric D Hsi; James R Cook; Mary Jo Lechowicz; Randy D Gascoyne; John P Leonard; Brad S Kahl; Bruce D Cheson; Richard I Fisher; Jonathan W Friedberg Journal: J Clin Oncol Date: 2016-04-11 Impact factor: 44.544
Authors: Peter J Hoskin; Lisa Lowry; Alan Horwich; Andrew Jack; Ben Mead; Barry W Hancock; Paul Smith; Wendi Qian; Philippa Patrick; Bilyana Popova; Andrew Pettitt; David Cunningham; Ruth Pettengell; John Sweetenham; David Linch; Peter W M Johnson Journal: J Clin Oncol Date: 2009-09-08 Impact factor: 44.544
Authors: Martin Hutchings; Lale Kostakoglu; Jan Maciej Zaucha; Bogdan Malkowski; Alberto Biggi; Iwona Danielewicz; Annika Loft; Lena Specht; Dominick Lamonica; Myron S Czuczman; Christina Nanni; Pier Luigi Zinzani; Louis Diehl; Richard Stern; Morton Coleman Journal: J Clin Oncol Date: 2014-07-28 Impact factor: 44.544
Authors: M Damlaj; S Ghazi; G Syed; T Pasha; G Gmati; H Salama; O Ali; K A Abuelgasim; M Al-Zahrani; A Hejazi; A Al Askar Journal: Bone Marrow Transplant Date: 2017-07-10 Impact factor: 5.483
Authors: Scott F Huntington; Gottfried von Keudell; Amy J Davidoff; Cary P Gross; Sapna A Prasad Journal: J Clin Oncol Date: 2018-10-04 Impact factor: 44.544